Irsenontrine maleate is a small molecule commercialized by Eisai, with a leading Phase II program in Lewy Body Dementia. According to Globaldata, it is involved in 6 clinical trials, which were completed. GlobalData uses proprietary data and analytics to provide a complete picture of Irsenontrine maleate’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Irsenontrine maleate is expected to reach an annual total of $10 mn by 2033 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Irsenontrine maleate Overview
E-2027 is under development for the treatment of dementia with lewy bodies and Parkinson's disease dementia. It is administered through oral route and formulated as a capsule. The drug candidate acts by targeting PDE9.
Eisai is a pharmaceutical company that discovers, develops, manufactures and markets pharmaceuticals, including prescription medicines, OTC drugs and generics. The company’s franchise areas in research include neurology and oncology. Eisai’s major products include Pariet/AcipHex, a proton pump inhibitor; Aricept, an anti-Alzheimer agent; perampanel, Halaven, an anti-cancer agent; Fycompa tablets for the treatment of epilepsy and peripheral neuropathy. Eisai has production plants in Japan, the UK, China and India and laboratories in Japan, the US and the UK; operations in the Americas, Asia and Latin America, EMEA and Oceania with overseas sales offices in the US, Germany, France, China and South Korea. Eisai is headquartered in Tokyo, Japan.
The company reported revenues of (Yen) JPY756,226 million for the fiscal year ended March 2022 (FY2022), an increase of 17.1% over FY2021. In FY2022, the company’s operating margin was 7.1%, compared to an operating margin of 8% in FY2021. In FY2022, the company recorded a net margin of 6.3%, compared to a net margin of 6.5% in FY2021. The company reported revenues of JPY187,572 million for the third quarter ended December 2022, an increase of 7.6% over the previous quarter.
For a complete picture of Irsenontrine maleate’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.